Re Vap and viral meningitis
It was argued that Biota could sell direct to hospitals with a small sales force and this would make it economic. Development of the drug would be done without support from a third party.
Given that retail sales/marketing costs may vastly exceed manufacturing costs, a drug sold through the cost sensitive retail market could well struggle. A direct to customer channel using a small sales force could well be very profitable. RP ran a strong line that if the target market would not easily support a product it would not be developed.
I think the chances are we already know whether vap is coming or going. Biota has had a long time to get a third party interest in the asthma treatment without any success. So it is definitely going unless another market can be found.
- Forums
- ASX - By Stock
- BTA
- todays meeting
todays meeting , page-38
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online